As of September 09, 2026, ADC Therapeutics's top three insider holders are Hans Peter Wild (TenPercentOwner, 9.79Mn shares), Hans Peter Wild (TenPercentOwner, 9.79Mn shares), Ameet Mallik (Chief Executive Officer, 2.12Mn shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Hans Peter Wild | TenPercentOwner | 9,788,944 | 0 | 9,788,944 | 62.0% | 15 May, 2025 |
| 2 | Ameet Mallik | Chief Executive Officer | 2,121,769 | 0 | 2,121,769 | 13.4% | 02 Jul, 2026 |
| 3 | Jose Carmona | Chief Financial Officer | 938,076 | 0 | 938,076 | 5.9% | 02 Jul, 2026 |
| 4 | Mohamed Zaki | Chief Medical Officer | 896,317 | 0 | 896,317 | 5.7% | 02 Jul, 2026 |
| 5 | Peter J Graham | Chief Legal Officer | 841,640 | 0 | 841,640 | 5.3% | 02 Jul, 2026 |
| 6 | Peter Hug | Director | 263,344 | 0 | 263,344 | 1.7% | 03 Jun, 2026 |
| 7 | Viviane Monges | Director | 186,447 | 0 | 186,447 | 1.2% | 03 Jun, 2026 |
| 8 | Thomas Pfisterer | Other | 173,899 | 0 | 173,899 | 1.1% | 15 May, 2025 |
| 9 | Victor Sandor | Director | 140,686 | 0 | 140,686 | 0.9% | 03 Jun, 2026 |
| 10 | Lisa Michelle Kallebo | Chief Accounting Officer | 128,224 | 0 | 128,224 | 0.8% | 18 Feb, 2026 |
| 11 | Ron Squarer | Director | 123,431 | 0 | 123,431 | 0.8% | 03 Jun, 2026 |
| 12 | Robert Azelby | Director | 112,805 | 0 | 112,805 | 0.7% | 03 Jun, 2026 |
| 13 | Timothy Coughlin | Director | 72,400 | 0 | 72,400 | 0.5% | 03 Jun, 2026 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 30 Jun, 2026 | Jose Carmona | Chief Financial Officer | Acquired A | 203,700 | $0.00 | $0 | 938,076 | Direct |
| 30 Jun, 2026 | Mohamed Zaki | Chief Medical Officer | Acquired A | 213,900 | $0.00 | $0 | 896,317 | Direct |
| 30 Jun, 2026 | Peter J Graham | Chief Legal Officer | Acquired A | 221,100 | $0.00 | $0 | 841,640 | Direct |
| 30 Jun, 2026 | Ameet Mallik | Chief Executive Officer | Acquired A | 675,000 | $0.00 | $0 | 2,121,769 | Direct |
| 01 Jun, 2026 | Jean-Pierre Bizzari | Director | Acquired A | 45,000 | $0.00 | $0 | 151,902 | Direct |
| 01 Jun, 2026 | Peter Hug | Director | Acquired A | 45,000 | $0.00 | $0 | 265,500 | Direct |
| 01 Jun, 2026 | Victor Sandor | Director | Acquired A | 45,000 | $0.00 | $0 | 153,286 | Direct |
| 01 Jun, 2026 | Timothy Coughlin | Director | Acquired A | 45,000 | $0.00 | $0 | 85,000 | Direct |
| 01 Jun, 2026 | Robert Azelby | Director | Acquired A | 45,000 | $0.00 | $0 | 125,405 | Direct |
| 01 Jun, 2026 | Viviane Monges | Director | Acquired A | 45,000 | $0.00 | $0 | 189,043 | Direct |
| 01 Jun, 2026 | Ron Squarer | Director | Acquired A | 45,000 | $0.00 | $0 | 138,627 | Direct |
| 03 Jun, 2026 | Jean-Pierre Bizzari | Director | Disposed F | 12,600 | $3.08 | $38.81K | 139,302 | Direct |
| 03 Jun, 2026 | Ron Squarer | Director | Disposed F | 15,196 | $3.08 | $46.80K | 123,431 | Direct |
| 03 Jun, 2026 | Peter Hug | Director | Disposed F | 2,156 | $3.08 | $6.64K | 263,344 | Direct |
| 03 Jun, 2026 | Viviane Monges | Director | Disposed F | 2,596 | $3.08 | $8.00K | 186,447 | Direct |
| 03 Jun, 2026 | Timothy Coughlin | Director | Disposed F | 12,600 | $3.08 | $38.81K | 72,400 | Direct |
| 03 Jun, 2026 | Robert Azelby | Director | Disposed F | 12,600 | $3.08 | $38.81K | 112,805 | Direct |
| 03 Jun, 2026 | Victor Sandor | Director | Disposed F | 12,600 | $3.08 | $38.81K | 140,686 | Direct |
| 13 Feb, 2026 | Mohamed Zaki | Chief Medical Officer | Acquired A | 285,200 | $3.99 | $1.14Mn | 707,020 | Direct |
| 13 Feb, 2026 | Jose Carmona | Chief Financial Officer | Acquired A | 271,600 | $3.99 | $1.08Mn | 760,256 | Direct |